Alterity Therapeutics Limited (PRNAF) Research

Alterity Therapeutics Limited, an Australian-based company, is dedicated to the discovery and development of pharmaceutical treatments for a range of neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases. The firm's leading experimental medication, ATH434, has successfully concluded its Phase I clinical trials for Parkinson's disease. Furthermore, Alterity is advancing PBT2, a compound that has already completed Phase IIa clinical trials targeting Alzheimer's disease. Formed in 1997 and headquartered in Melbourne, Australia, the company rebranded from Prana Biotechnology Limited to Alterity Therapeutics Limited in April 2019.

Market snapshot

Symbol
PRNAF
Price
$0.06
Day change
0.00%
Market cap
$130.5M
P/E ratio
-8.37x
52-week range
0.0009-0.695
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Actinogen Medical Limited (ATGGF)
  • BioStem Technologies, Inc. (BSEM)
  • Calliditas Therapeutics Ab (CLTEF)
  • Helix BioPharma Corp. (HBPCF)
  • Imugene Limited (IUGNF)
  • Satellos Bioscience Inc. (MSCLF)
  • Nicox S.A. (NICXF)
  • IXICO plc (PHYOF)

Open Alterity Therapeutics Limited (PRNAF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.